Xenetic Biosciences (XBIO)
NASDAQ:XBIO
Want to see XBIO full AI Analyst Report?
Top Page
Xenetic Biosciences
(NASDAQ:XBIO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$3.00
▲(35.75% Upside)
Action:Reiterated
Date:05/14/26
The score is mainly held down by weak financial performance (ongoing losses and negative cash flow) and limited valuation support (negative P/E, no dividend). Partially offsetting this are a debt-free balance sheet and mildly positive technical trends, with a small positive contribution from the recent executive equity award.
Positive Factors
Debt-free balance sheet
A zero-debt capital structure reduces refinancing and interest-rate risks, giving management flexibility to fund R&D or operations via equity or partnerships. This durable strength materially lowers bankruptcy risk and supports runway while the company pursues commercialization milestones.
Negative Factors
Deep and persistent unprofitability
Large negative net margins reflect chronic inability to convert revenues into profits, implying the company must either materially cut operating spend or deliver major revenue gains to reach break-even. Over a multi-month horizon this limits self-funding and raises execution risk for clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt capital structure reduces refinancing and interest-rate risks, giving management flexibility to fund R&D or operations via equity or partnerships. This durable strength materially lowers bankruptcy risk and supports runway while the company pursues commercialization milestones.
Read all positive factors
Xenetic Biosciences (XBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.06M
Dividend YieldN/A
Average Volume (3M)1.70M
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth23.52%
EPS Growth48.34%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.50
Price to Sales (P/S)1.24
P/FCF Ratio-1.61
Enterprise Value/Market Cap-0.22
Enterprise Value/Revenue-0.48
Enterprise Value/Gross Profit-0.48
Enterprise Value/Ebitda0.64
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.32
Revenue Forecast (FY)$3.00M
Xenetic Biosciences Business Overview & Revenue Model
Company Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the dis...
How the Company Makes Money
null...
Xenetic Biosciences Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.19M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| Gross Profit | 3.19M | 2.98M | 2.50M | 2.54M | 1.71M | 1.16M |
| EBITDA | -2.37M | -2.83M | -4.05M | -4.52M | -6.69M | -5.71M |
| Net Income | -2.23M | -2.68M | -3.96M | -4.13M | -6.55M | -5.65M |
Balance Sheet | ||||||
| Total Assets | 7.91M | 8.36M | 6.90M | 10.61M | 14.72M | 19.82M |
| Cash, Cash Equivalents and Short-Term Investments | 7.35M | 7.88M | 6.17M | 8.98M | 13.10M | 18.24M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.04K |
| Total Liabilities | 958.24K | 968.02K | 894.26K | 809.59K | 1.07M | 1.42M |
| Stockholders Equity | 6.95M | 7.40M | 6.01M | 9.80M | 13.65M | 18.39M |
Cash Flow | ||||||
| Free Cash Flow | -1.82M | -2.29M | -2.82M | -4.11M | -5.15M | -4.74M |
| Operating Cash Flow | -1.82M | -2.29M | -2.82M | -4.11M | -4.65M | -4.74M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -500.00K | 0.00 |
| Financing Cash Flow | 4.00M | 4.00M | 0.00 | 0.00 | 0.00 | 11.45M |
Xenetic Biosciences Technical Analysis
Positive
2.21
Price Trends
3.07
Positive
2.72
Positive
2.93
Positive
Market Momentum
>-0.01
Negative
52.19
Neutral
76.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XBIO, the sentiment is Positive. The current price of 2.21 is below the 20-day moving average (MA) of 3.04, below the 50-day MA of 3.07, and below the 200-day MA of 2.93, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.19 is Neutral, neither overbought nor oversold. The STOCH value of 76.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XBIO.
Xenetic Biosciences Risk Analysis
Xenetic Biosciences disclosed 67 risk factors in its most recent earnings report. Xenetic Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xenetic Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $13.06M | -2.69 | -102.39% | ― | 356.16% | 62.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $22.68M | -1.37 | -74.15% | ― | -24.96% | 46.11% | |
49 Neutral | $7.06M | -3.16 | -60.33% | ― | 23.52% | 48.34% | |
49 Neutral | $11.33M | -0.60 | -87.05% | ― | -90.40% | 34.76% |
* Healthcare Sector Average
XBIO
Xenetic Biosciences
3.08
0.08
2.67%
ERNA
Eterna Therapeutics
11.66
-70.09
-85.74%
VYNE
VYNE Therapeutics
0.69
-0.26
-27.79%
APRE
Aprea Therapeutics
0.93
-0.81
-46.55%
HCWB
HCW Biologics
2.09
-5.64
-72.96%
Xenetic Biosciences Corporate Events
Executive/Board Changes
Xenetic Biosciences Grants Equity Award to Interim CEO
Positive
Apr 24, 2026
On April 21, 2026, Xenetic Biosciences, Inc. granted Interim Chief Executive Officer and Chief Financial Officer James Parslow an award of 100,000 shares of restricted stock under its Amended and Restated Equity Incentive Plan. Of these shares, 7,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.